Emmaus Life Sciences, Inc. (EMMA)
2025-06-30 | 2025-03-31 | 2024-09-30 | ||
|---|---|---|---|---|
| Revenues, net | 2,817 | 2,406 | 5,478 | |
| Cost of goods sold | 150 | 225 | 394 | |
| Gross profit | 2,667 | 2,181 | 5,084 | |
| Selling | 674 | 646 | 1,318 | |
| Research and development | 56 | 176 | 146 | |
| General and administrative | 2,307 | 2,339 | 2,799 | |
| Total operating expenses | 3,037 | 3,161 | 4,263 | |
| Income (loss) from operations | -370 | -980 | 821 | |
| Change in fair value of conversion feature derivative, notes payable | - | 162 | 2,277 | |
| Interest expense | 1,678 | 1,256 | 1,338 | |
| Interest and other income (net) | 67 | 73 | 145 | |
| Loss on debt extinguishment | -212 | -164 | - | |
| Foreign exchange gain (loss) | 134 | -152 | -117 | |
| Change in fair value of warrant derivative liabilities | 4 | -9 | 38 | |
| Gain on lease modification | 861 | - | - | |
| Realized loss on investment in convertible bond | -531 | - | - | |
| Total other expense | -1,355 | -1,346 | 1,005 | |
| Loss before income taxes | -1,725 | -2,326 | 1,826 | |
| Income tax provision (benefit) | -590 | 4 | -1 | |
| Net loss | -1,135 | -2,330 | 1,827 | |
| Unrealized gain (loss) on debt securities available for sale (net of tax) | 3,715 | 194 | 1,397 | |
| Foreign currency translation adjustment | -33 | 4 | -19 | |
| Reclassification adjustment for loss included in net income (loss) | 354 | - | - | |
| Other comprehensive income (loss) | 4,036 | 198 | 1,378 | |
| Comprehensive income (loss) | 2,901 | -2,132 | 3,205 | |
| Earnings per share, basic, total | -0.02 | -0.04 | 0.03 | |
| Earnings per share, diluted, total | -0.02 | -0.04 | -0.01 | |
| Weighted average number of shares outstanding, basic, total | 63,865,571 | 63,865,571 | 63,865,571 | |
| Weighted average number of shares outstanding, diluted, total | 63,865,571 | 63,865,571 | 162,726,685 | |